Vaxformer: Antigenicity-controlled Transformer for Vaccine Design Against SARS-CoV-2

• URL: http://arxiv.org/abs/2305.11194v1
• Date: Thu, 18 May 2023 13:36:57 GMT
• Title: Vaxformer: Antigenicity-controlled Transformer for Vaccine Design Against SARS-CoV-2
• Authors: Aryo Pradipta Gema, Micha{\l} Kobiela, Achille Fraisse, Ajitha Rajan, Diego A. Oyarz\'un, Javier Antonio Alfaro
• Abstract summary: The present study proposes a novel conditional protein Language Model architecture, called Vaxformer. Vaxformer is designed to produce natural-looking antigenicity-controlled SARS-CoV-2 spike proteins.
• Score: 0.6850683267295248
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: The SARS-CoV-2 pandemic has emphasised the importance of developing a universal vaccine that can protect against current and future variants of the virus. The present study proposes a novel conditional protein Language Model architecture, called Vaxformer, which is designed to produce natural-looking antigenicity-controlled SARS-CoV-2 spike proteins. We evaluate the generated protein sequences of the Vaxformer model using DDGun protein stability measure, netMHCpan antigenicity score, and a structure fidelity score with AlphaFold to gauge its viability for vaccine development. Our results show that Vaxformer outperforms the existing state-of-the-art Conditional Variational Autoencoder model to generate antigenicity-controlled SARS-CoV-2 spike proteins. These findings suggest promising opportunities for conditional Transformer models to expand our understanding of vaccine design and their role in mitigating global health challenges. The code used in this study is available at https://github.com/aryopg/vaxformer .

Related papers

• Immunogenicity Prediction with Dual Attention Enables Vaccine Target Selection [6.949493332885247]
  ProVaccine is a novel deep learning solution that integrates latent vector representations of protein sequences and structures. We also compile the most comprehensive immunogenicity dataset to date, encompassing over 9,500 antigen sequences, structures, and immunogenicity labels from bacteria, viruses, and tumors. Our work provides an effective tool for vaccine design and sets valuable benchmarks for future research.
  arXiv  Detail & Related papers  (2024-10-03T16:33:35Z)
• Opponent Shaping for Antibody Development [49.26728828005039]
  Anti-viral therapies are typically designed to target only the current strains of a virus. therapy-induced selective pressures act on viruses to drive the emergence of mutated strains, against which initial therapies have reduced efficacy. We build on a computational model of binding between antibodies and viral antigens to implement a genetic simulation of viral evolutionary escape.
  arXiv  Detail & Related papers  (2024-09-16T14:56:27Z)
• Agent-Based Model: Simulating a Virus Expansion Based on the Acceptance of Containment Measures [65.62256987706128]
  Compartmental epidemiological models categorize individuals based on their disease status. We propose an ABM architecture that combines an adapted SEIRD model with a decision-making model for citizens. We illustrate the designed model by examining the progression of SARS-CoV-2 infections in A Coruna, Spain.
  arXiv  Detail & Related papers  (2023-07-28T08:01:05Z)
• Dense Feature Memory Augmented Transformers for COVID-19 Vaccination Search Classification [60.49594822215981]
  This paper presents a classification model for detecting COVID-19 vaccination related search queries. We propose a novel approach of considering dense features as memory tokens that the model can attend to. We show that this new modeling approach enables a significant improvement to the Vaccine Search Insights (VSI) task.
  arXiv  Detail & Related papers  (2022-12-16T13:57:41Z)
• xTrimoABFold: De novo Antibody Structure Prediction without MSA [77.47606749555686]
  We develop a novel model named xTrimoABFold to predict antibody structure from antibody sequence. The model was trained end-to-end on the antibody structures in PDB by minimizing the ensemble loss of domain-specific focal loss on CDR and the frame-aligned point loss.
  arXiv  Detail & Related papers  (2022-11-30T09:26:08Z)
• Constrained Submodular Optimization for Vaccine Design [1.7622426179653559]
  Genetic variability makes it difficult to design peptide vaccines that provide widespread immunity in vaccinated populations. We introduce a framework for evaluating and designing peptide vaccines that uses probabilistic machine learning models. We demonstrate its ability to produce designs for a SARS-CoV-2 vaccine that outperform previous designs.
  arXiv  Detail & Related papers  (2022-06-16T17:40:54Z)
• Using Deep Learning Sequence Models to Identify SARS-CoV-2 Divergence [1.9573380763700707]
  SARS-CoV-2 is an upper respiratory system RNA virus that has caused over 3 million deaths and infecting over 150 million worldwide as of May 2021. We propose a neural network model that leverages recurrent and convolutional units to take in amino acid sequences of spike proteins and classify corresponding clades.
  arXiv  Detail & Related papers  (2021-11-12T07:52:11Z)
• PhyloTransformer: A Discriminative Model for Mutation Prediction Based on a Multi-head Self-attention Mechanism [10.468453827172477]
  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an ongoing pandemic infecting 219 million people as of 10/19/21, with a 3.6% mortality rate. Here we developed PhyloTransformer, a Transformer-based discriminative model that engages a multi-head self-attention mechanism to model genetic mutations that may lead to viral reproductive advantage.
  arXiv  Detail & Related papers  (2021-11-03T01:30:57Z)
• A k-mer Based Approach for SARS-CoV-2 Variant Identification [55.78588835407174]
  We show that preserving the order of the amino acids helps the underlying classifiers to achieve better performance. We also show the importance of the different amino acids which play a key role in identifying variants and how they coincide with those reported by the USA's Centers for Disease Control and Prevention (CDC)
  arXiv  Detail & Related papers  (2021-08-07T15:08:15Z)
• Designing a Prospective COVID-19 Therapeutic with Reinforcement Learning [50.57291257437373]
  SARS-CoV-2 pandemic has created a global race for a cure. One approach focuses on designing a novel variant of the human angiotensin-converting enzyme 2 (ACE2) We formulate a novel protein design framework as a reinforcement learning problem.
  arXiv  Detail & Related papers  (2020-12-03T07:35:38Z)
• PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with conditional generative models [2.0750380105212116]
  With the fast development of COVID-19 into a global pandemic, scientists around the globe are desperately searching for effective antiviral therapeutic agents. We propose a deep learning framework for conditional de novo design of antiviral candidate drugs tailored against given protein targets.
  arXiv  Detail & Related papers  (2020-05-27T11:30:15Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.